Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran. // Value in Health Regional Issues. – URL: https://www.sciencedirect.com/science/article/pii/S2212109926005522?dgcid=rss_sd_all
Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran. Value in Health Regional Issues. https://www.sciencedirect.com/science/article/pii/S2212109926005522?dgcid=rss_sd_all
“Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran.” Value in Health Regional Issues.
@article{article70870,
title = {Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran},
journal = {Value in Health Regional Issues},
url = {https://www.sciencedirect.com/science/article/pii/S2212109926005522?dgcid=rss_sd_all}
}